Management of advanced non-small-cell-lungcancer (NSCLC) is still a challenge to clinicians, with poor response rate to chemotherapy and ominous prognosis. Many antineoplastic agents, including ifosfamide, navelbine, docetaxel and paclitaxel etc. have been demonstrated to be clinically active, and some of which have been put into clinical use in our country recently. Among these drugs, paclitaxel is thought to be one of the most promising agents in this category. Its price, however, is now hardly acceptable in China and severely hinders its wide use. From Feb. 1994 through Jan 1996, we applied paclitaxel plus cisplatin regimen to four patients with advanced NSCLC, and following is a report of our preliminary experience.